Refractory or Relapsed Multiple Myeloma
5 clinical trials · Condition
◉ Watch Refractory or Relapsed Multiple Myeloma
| Record | Firm | Date |
|---|---|---|
| A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma (NCT06952478) | Celltrion | 2025-08-12 |
| LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (NCT03674463) | Second Affiliated Hospital of Xi'an Jiaotong University | 2018-07-26 |
| Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma (NCT03716856) | First Affiliated Hospital of Zhejiang University | 2018-03-23 |
| Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma (NCT03380039) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2017-10-13 |
| LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (NCT03090659) | Nanjing Legend Biotech Co. | 2015-10-02 |
Track Refractory or Relapsed Multiple Myeloma automatically
Every clearance here is in the API, with alerts when new ones post.